Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefapixant in refractory chronic cough
NCT02612623Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2015
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gefapixant in refractory chronic cough (RCC), sponsored by Merck & Co.. Started Dec 2015; status: completed.
02
Drugs
gefapixant
03
Conditions
refractory chronic cough (RCC)
Beyond the preview
Go deeper on NCT02612623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02612623.